|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: RAPAMUNE
Summary for Tradename: RAPAMUNE
|
| |||||||
Clinical Trials for: RAPAMUNEProspective Study of Rapamycin for the Treatment of SLE Status: Recruiting Condition: Systemic Lupus Erythematosus (SLE) Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Status: Recruiting Condition: Glioma Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors Status: Recruiting Condition: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Status: Recruiting Condition: Advanced Cancer; Solid Tumor A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers Status: Recruiting Condition: Advanced Solid Cancers Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium Status: Active, not recruiting Condition: Bladder Cancer; Metastatic Transitional Cell Carcinoma A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Status: Terminated Condition: Desmoid Tumor RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer Status: Active, not recruiting Condition: HEAD & NECK Cancer BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Status: Recruiting Condition: Renal Cell Carcinoma Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Status: Active, not recruiting Condition: Waldenstrom's Macroglobulinemia Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Pharms Inc | RAPAMUNE | sirolimus | SOLUTION; ORAL | 021083 | Sep 15, 1999 | RX | Yes | 5,100,899*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wyeth Pharms Inc | RAPAMUNE | sirolimus | SOLUTION; ORAL | 021083 | Sep 15, 1999 | RX | Yes | 5,403,833*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wyeth Pharms Inc | RAPAMUNE | sirolimus | SOLUTION; ORAL | 021083 | Sep 15, 1999 | RX | Yes | 5,536,729*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wyeth Pharms Inc | RAPAMUNE | sirolimus | TABLET; ORAL | 021110 | Aug 22, 2002 | RX | Yes | 5,100,899*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: RAPAMUNE
| Drugname | Dosage | Strength | RLD | Submissiondate |
| sirolimus | Tablets | 0.5 mg | Rapamune | 8/25/2010 |
| sirolimus | Tablets | 1 mg and 2 mg | Rapamune | 12/17/2009 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc